Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3273004 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL10631088 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL148701 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL10579468 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL9436902 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL352163 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL8436544 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL6758775 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL22325587 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 | |
| SCHEMBL7605212 | 1.00 | EPHX1 (0.48) | EPHX1FAAHSMN1; SMN2ACE2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | claimed |
| WO-2023175356-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | POLITECHNIKA WROCLAWSKA (PL) | 2023-09-21 | — | — | WO | claimed |
| US-9028966-B2 | Silicone fine particles and production method thereof | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-05-12 | — | — | US | claimed |
| EP-2581415-B1 | Silicone Fine Particles and Production Method Thereof | SHINETSU CHEMICAL CO (JP) | 2014-02-26 | — | — | EP | claimed |
| US-20130095324-A1 | SILICONE FINE PARTICLES AND PRODUCTION METHOD THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-18 | — | — | US | claimed |
| EP-2581415-A1 | Silicone Fine Particles and Production Method Thereof | Shin-Etsu Chemical Co., Ltd. (JP) | 2013-04-17 | — | — | EP | claimed |
| EP-1531819-A1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | claimed |
| EP-0577682-A1 | SMALL PEPTIDIC COMPOUNDS USEFUL FOR THE TREATMENT OF GLAUCOMA | CARLBIOTECH LTD. A/S (DK) | 1994-01-12 | — | — | EP | claimed |
| WO-1992016551-A1 | SMALL PEPTIDIC COMPOUNDS USEFUL FOR THE TREATMENT OF GLAUCOMA | CARLBIOTECH LTD. A/S (DK) | 1992-10-01 | — | — | WO | claimed |
| CN-122005761-A | Methods of treating diseases and conditions using interleukin-10 | 阿尔莫生物科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12351605-B2 | Optically controllable FGFR stimulation using wireless controlled cellular lighting system | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | disclosed |
| US-11993099-B2 | Ballpoint pen | KABUSHIKI KAISHA PILOT CORPORATION (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-0577682-A1 | SMALL PEPTIDIC COMPOUNDS USEFUL FOR THE TREATMENT OF GLAUCOMA | CARLBIOTECH LTD. A/S (DK) | 1994-01-12 | — | — | EP | disclosed |
| EP-0276872-B1 | ELECTRODEPOSITION COATING COMPOSITION CONTAINING A MODIFIED EPOXY RESIN HAVING CHARGEABLE GROUPS | Nippon Paint Co., Ltd. (JP) | 1992-12-30 | — | — | EP | disclosed |
| WO-1992016551-A1 | SMALL PEPTIDIC COMPOUNDS USEFUL FOR THE TREATMENT OF GLAUCOMA | CARLBIOTECH LTD. A/S (DK) | 1992-10-01 | — | — | WO | disclosed |
| US-4829105-A | GRAFT POLYMERS, ANIONIC, HYDROPHILIC | NIPPON PAINT CO., LTD. (JP) | 1989-05-09 | — | — | US | disclosed |
| EP-0276872-A2 | Electrodeposition coating composition containing a modified epoxy resin having chargeable groups | Nippon Paint Co., Ltd. (JP) | 1988-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358951-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | EPHX1 4713/4885FAAH 4064/4885SMN1; SMN2 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.